Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CX-904 |
| Synonyms | |
| Therapy Description |
CX-904 comprises a bispecific antibody targeting both EGFR and CD3 linked to masking peptide that is cleaved by tumor-specific proteases in the tumor microenvironment, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CX-904 | CX 904|CX904|AMG 651|AMG651|AMG-651 | CD3 Antibody 119 EGFR Antibody 73 | CX-904 comprises a bispecific antibody targeting both EGFR and CD3 linked to masking peptide that is cleaved by tumor-specific proteases in the tumor microenvironment, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05387265 | Phase I | CX-904 | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | Terminated | USA | 0 |